Viatris Inc. Share Price

Equities

VTRS

US92556V1061

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 19/07/2024 BST 5-day change 1st Jan Change
11.84 USD +0.59% Intraday chart for Viatris Inc. +5.34% +9.33%
Sales 2024 * 14.85B 1,150B Sales 2025 * 14.55B 1,127B Capitalization 14.1B 1,092B
Net income 2024 * 1.81B 140B Net income 2025 * 791M 61.27B EV / Sales 2024 * 1.83 x
Net Debt 2024 * 13.07B 1,013B Net Debt 2025 * 11.23B 869B EV / Sales 2025 * 1.74 x
P/E ratio 2024 *
9.03 x
P/E ratio 2025 *
16.9 x
Employees 33,000
Yield 2024 *
4.24%
Yield 2025 *
4.36%
Free-Float 96.36%
More Fundamentals * Estimated data
Dynamic Chart
1 day+0.59%
1 week+5.34%
Current month+11.38%
1 month+15.40%
3 months+5.24%
6 months+3.86%
Current year+9.33%
More quotes
1 week
10.94
Extreme 10.935
12.16
1 month
10.15
Extreme 10.145
12.16
Current year
9.93
Extreme 9.925
13.62
1 year
8.74
Extreme 8.74
13.62
3 years
8.42
Extreme 8.42
15.60
5 years
8.42
Extreme 8.42
23.11
10 years
8.42
Extreme 8.42
76.69
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 28/12/22
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - 15/11/20
Members of the board TitleAgeSince
Chairman 56 15/11/20
Director/Board Member 68 15/11/20
Director/Board Member 66 15/11/20
More insiders
Date Price Change Volume
19/07/24 11.84 +0.59% 5,500,279
18/07/24 11.77 -0.59% 6,950,787
17/07/24 11.84 +4.04% 11,282,481
16/07/24 11.38 +3.45% 9,488,505
15/07/24 11 -2.14% 5,438,821

Delayed Quote Nasdaq, July 19, 2024 at 09:00 pm

More quotes
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s ARV franchise. The Company’s portfolio comprises approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands and generics, including complex products. The Company operates manufacturing sites across worldwide that produce oral solid doses, injectables and complex dosage forms.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
11.84 USD
Average target price
12.65 USD
Spread / Average Target
+6.81%
Consensus